Researchers at Helmholtz Munich developed a hybrid molecule using GLP-1/GIP signaling to treat obesity and type 2 diabetes.
← News
Medicine Breakthroughs Medicine Breakthroughs Health
One molecule, two effects: A new drug concept to treat obesity and type 2 diabetes
GLP-1/GIP Signaling Pathway With Metabolic Modulator Drug mechanism
Laboratory Mice Test subjects
Reduced Appetite, Weight Loss, Improved Glucose Control Outcomes